Concepedia

Kimiyo Tabata

KT

Statistics

Publications

8

Citations

918

H-Index

8

Active since

1986

Affiliations

Eisai (Japan)(Current)

Eisai (United States)

Kimiyo Tabata is an author at Eisai (Japan) specializing in immunotherapy, oncology, and medicine.

ORCID

Publications per year

1986–2024

8

Publications

8

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato, Kimiyo Tabata, Takayuki Kimura et al. · PLoS ONE · 2019 · 463 citations · Full text

, , +17

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science · 2018 · 342 citations · Full text

, , +17

Lenvatinib mesilate (LEN) enhanced antitumor activity of a PD-1 blockade agent by potentiating Th1 immune response

Yu Kato, Xiaoyi Bao, S. Macgrath et al. · Annals of Oncology · 2016 · 42 citations

, , +17

Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors

Yu Kato, Kimiyo Tabata, Yusaku Hori et al. · Molecular Cancer Therapeutics · 2015 · 16 citations

, , +17

A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency

Shinji Kohsaka, Shigehiro Yagishita, Yukina Shirai et al. · npj Precision Oncology · 2024 · 15 citations · Full text

, , +17

1–5 of 8